Compare HBB & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBB | DCTH |
|---|---|---|
| Founded | 1904 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.9M | 350.7M |
| IPO Year | 2017 | N/A |
| Metric | HBB | DCTH |
|---|---|---|
| Price | $16.75 | $10.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $22.60 |
| AVG Volume (30 Days) | 30.8K | ★ 508.5K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | ★ 24.53 | N/A |
| EPS | ★ 2.34 | 0.03 |
| Revenue | ★ $607,430,000.00 | $79,603,000.00 |
| Revenue This Year | N/A | $131.69 |
| Revenue Next Year | N/A | $39.22 |
| P/E Ratio | ★ $7.06 | $294.73 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $12.72 | $8.12 |
| 52 Week High | $21.20 | $18.23 |
| Indicator | HBB | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 55.82 |
| Support Level | $15.62 | $9.98 |
| Resistance Level | $17.23 | $10.37 |
| Average True Range (ATR) | 0.75 | 0.39 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 52.77 | 49.00 |
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.